8-Substituted Theopyllines as Inhibitors of Steroid Hormone Receptor Action in Cancer and Other Diseases
- Detailed Technology Description
- The disclosure herein relates to nuclear hormone receptors including steroid hormone receptors, for example in connection with estrogen, progesterone, and androgen.
- Countries
- United States
- Application No.
- 8871751
- *Abstract
-
The disclosure herein relates to nuclear hormone receptors including steroid hormone receptors, for example in connection with estrogen, progesterone, and androgen. Embodiments of compositions and methods are disclosed including such relating to compounds, including substituted theophyllines, capable of functioning as inhibitors of estrogen receptor alpha-mediated gene expression and having the ability to modify cancer cells and treat cancer, including breast cancer and resistant breast cancers, particularly those that are resistant to tamoxifen. In embodiments, methods of inhibiting breast cancer cells and resistant breast cancer cells are provided. In embodiments, a useful inhibitor compound includes TPSF/NSC 97998 and other compounds.
For more information about this technology, please contact the University of Illinois at Urbana-Champaign at otm@illinois.edu.
- *IP Issue Date
- None
- *IP Type
- Utility
- Country/Region
- USA
